Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-11-18

Clinical Trial Update: A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate Asthma [Phase 2]

View source ↗

Summary

This is a completed Phase 2 study evaluating the effect of fingolimod (FTY720) on pulmonary function in adults with moderate asthma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GILENYA (FINGOLIMOD HCL)

Snippet

Sponsor: Novartis | Conditions: Asthma | Phase 2 | Status: COMPLETED